Hepatitis B vaccine recombinant - VBI Vaccines

Drug Profile

Hepatitis B vaccine recombinant - VBI Vaccines

Alternative Names: Bio-Hep-B; Hepimmune; Sci-B-Vac

Latest Information Update: 21 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Weizmann Institute of Science
  • Developer VBI Vaccines
  • Class Hepatitis B vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 19 Apr 2018 VBI Vaccines completes enrolment in the phase III PROTECT trial for Hepatitis B in USA, Canada and Europe (IM)
  • 19 Dec 2017 VBI Vaccines plans to submit marketing authorisation applications to the regulatory bodies in USA, Canada and the EU for Hepatitis B in 2019
  • 18 Dec 2017 Phase-III clinical trials in Hepatitis B in USA, Europe, Canada (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top